Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324066 | 0.99 | TSHR (0.41) | LMNASMN1; SMN2KMT2AALDH1A1MEN1 | |
| SCHEMBL6315276 | 0.92 | LMNA (0.42) | LMNASMN1; SMN2KMT2AALDH1A1ALOX15 | |
| SCHEMBL6316289 | 0.91 | KCNH2 (0.39) | LMNASMN1; SMN2KMT2AMEN1ALOX5 | |
| SCHEMBL6316049 | 0.91 | SIGMAR1 (0.45) | LMNASMN1; SMN2TSHR | |
| SCHEMBL6316994 | 0.91 | LMNA (0.43) | LMNASMN1; SMN2KMT2AALDH1A1POLB | |
| SCHEMBL6314259 | 0.91 | MET (0.41) | LMNASMN1; SMN2KMT2AALDH1A1ALOX15 | |
| SCHEMBL6315004 | 0.91 | ALDH1A1 (0.44) | LMNASMN1; SMN2KMT2AALDH1A1ALOX15 | |
| SCHEMBL6316014 | 0.90 | SIGMAR1 (0.44) | LMNASMN1; SMN2TSHR | |
| SCHEMBL6321106 | 0.90 | MET (0.41) | LMNASMN1; SMN2KMT2AALDH1A1ALOX15 | |
| SCHEMBL6322800 | 0.90 | ALDH1A1 (0.43) | LMNASMN1; SMN2KMT2AALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951848-B2 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC., (US) | 2005-10-04 | — | — | US | claimed |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | claimed |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | claimed |
| US-6951848-B2 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC., (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1377549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002072549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | LMNA 4828/4885SMN1; SMN2 4576/4885KMT2A 4021/4885 |
| US-20050075348-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | LMNA 4803/4885SMN1; SMN2 4694/4885KMT2A 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.